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A multimodal stepped care approach has been successfully applied to a patient with complex regional pain syndrome type 1 and
severe intractable pain, not responding to regular neuropathic pain medication. The choice to administer drugs in creams was
made because of the intolerable adverse eﬀects to oral medication. With this method, peak-dose adverse eﬀects did not occur. The
multimodal stepped care approach resulted in considerable and clinically relevant decrease in pain after every step, using topical
amitriptyline, ketamine, and dimethylsulphoxide.
1.Introduction
Complex regional pain syndrome (CRPS) is a challenging
pain syndrome usually starting after a trauma or surgery.
Two types of CRPS are distinguished: CRPS type 1 (CRPS-1)
without demonstrable nerve lesions and related to a trauma
and CRPS type 2 based on objective nerve damage, most
commonly caused by severe trauma. CRPS-1 is recently
recognized as a chronic neuropathic pain syndrome and typ-
ically develops in an extremity after tissue trauma [1]. CRPS
type 2 is formerly known as causalgia, while CRPS-1 is
formerly known as Sudeck’s atrophy, algodystrophy, post-
traumatic dystrophy, and reﬂex sympathetic dystrophy. Be-
sides the neuropathic pain symptoms, such as burning pain
and allodynia, CRPS is associated with autonomic, trophic,
and motor function changes. Consequently, the following
symptoms in the aﬀected region can occur: edema, altered
sweating, skin color, and skin temperature, changes to the
skin,hair,andnails,lossofstrength,decreasedactiverangeof
motion, and tremor. The estimated incidence is 5.46 to 26.2
new cases per 100,000 annually [2, 3]. The current under-
standing of the pathophysiology of CRPS is that multiple
mechanisms are involved, such as reduced density of C-
and Aδ-ﬁbers, central and peripheral sensitization, altered
vasomotor function, changes in catecholamine concentra-
tion and its receptors, increased inﬂammatory and decreased
anti-inﬂammatory factors, decreased representation on the
somatosensory cortex, genetic predisposition, and psycho-
logical factors [1].
Many therapies have been evaluated, though no medical
treatment has shown robust eﬃcacy [1, 4]. Interdisciplinary
approach for functional restoration, pain management, and
psychological support can enhance the chance of full recov-
ery [1, 5]. This is clearly an important issue, as incomplete
resolution of signs and symptoms is common and only one-
third of the patients reach full recovery [6]. Therefore multi-
modal therapy, an emerging method in the treatment of
neuropathic pain [7, 8], is also explored for treating intra-
ctable pain in CRPS patients.
This paper details successful treatment of a CRPS-1 pa-
tient with severe intractable neuropathic pain, following a
multimodal stepped care approach, using creams of amitri-
ptyline, ketamine, and dimethylsulphoxide (DMSO).2 Case Reports in Medicine
2.CaseReport
A 42-year-old Caucasian male was referred to our Institute
for Neuropathic Pain with complaints of severe intractable
pain around the left ankle. Progressive pain developed in
November 2007, two months after a fall from the stairs.
The immediate symptoms following the fall were a massive
edema and hematoma of the left leg, with signs and symp-
toms of an ankle distortion. Subsequently he was diagnosed
with CRPS-1. At the time of diagnosis the left ankle was
colderthanthesurrounding tissue,andtrophicchangeswere
apparent. Symptoms of neuropathic pain, such as pricking,
tingling, shooting pain, hyperalgesia, and allodynia, were
present.MRIscans,X-rays,lumbarpunction,andlaboratory
blood tests did not reveal any pathology, thus supporting the
diagnosis of CRPS-1. Nerve conduction studies revealed a
slight distal motor latency of the nervus peronaeus superﬁ-
cialis, but no signiﬁcant diﬀerence was observed between the
left nerve and the right nerve.
Analgesics such as gabapentin, pregabalin, tramadol, and
NSAIDs (nonsteroidal anti-inﬂammatory drugs), all given in
the highest dosages, were not eﬀective. The patient experi-
encedonlyadverseeﬀects,suchasdrowsinessandfeelinglike
a zombie. As a matter of fact, high dose of tramadol resulted
in hospitalization due to an opiate-induced ileus. Only
amitriptyline 25mg orally was somewhat eﬀective in pain
reduction, however the adverse eﬀects limited its further use.
On the 19th of May 2010, at his ﬁrst visit to our institute,
he complained of severe pain. The pain score was 9 out of
10 on the 11-point numerical rating scale (NRS), where 0
is total absence of pain and 10 is the worst pain imaginable.
Ontheshort-formMcGillPainQuestionnaire(SF-MPQ),he
scored26 outof 45 withthe following severe pain symptoms:
stabbing, sharp, tender, tiring-exhausting, and fearful. On
the Neuropathic Pain Symptom Inventory (NPSI), he scored
44outof100(withinthisscalehissubscoresontheNRSwere
squeezing 7, pressure 7, stabbing 8, tingling 8, provocation of
increaseof painby pressure7, andprovocation bysomething
cold 7). According to the part of the Brief Pain Inventory
(BPI) concerning interference of pain with the patient’s life,
the pain interfered profoundly with daily activities as shown
in Table 1.
Neurological examination was normal, apart from allo-
dynia after the tuning fork test on the left maleolus lateralis,
as well as after light rubbing on the painful area. We decided
to prescribe amitriptyline 5% cream three times daily, be-
cause the pain had components of neuropathic pain, such as
allodynia,hyperalgesia,tingling,andstabbing.Previously,on
oral amitriptyline the patient experienced some relief; how-
ever, he also experienced dose-limiting adverse eﬀects, most
probably peak-dose eﬀects. Therefore, we decided to apply
amitriptyline topically, because amitriptyline cream acts as
a slow-release formulation [9]. One month later his overall
pain score on the NRS decreased about 30%, from 9 to 6 or
7, without any adverse eﬀects.
Ketamine cream has been found to be eﬀective in CRPS
patients in some pilot trials [10, 11], and thus we decided
to add topical ketamine 10% cream 3 times daily. After one
month the overall pain was further reduced to 5 on the NRS.
Table 1: Interference of pain in patient’s life.
19-5-2010 27-10-2010
General activity 7 1.5
Mood 6 4
Walking 7 1.5
Work 10 1.5
Relations with others 2 0
Sleep 6 0
Enjoy 8 0
0: does not interfere and 10: interferes completely.
The third cream, DMSO 50%, was added because of
positive studies on CRPS patients [12–14], and because
DMSO acts as a penetration enhancer for topical drugs [15].
One month later the pain decreased further by more than
50%, to 3 on the NRS. During the last evaluation, on 27th
of October 2010, he reported that the pain was virtually
gone, with the total pain score of 1.5 on the NRS. This pain
relief lasted 4 months while using the creams 3 times daily.
Thereafter the patient gradually reduced the frequency of
application and is applying the 3 creams now only in the
morning with sustained alleviation in the last 8 months.
Altogether, in 5 months of treatment; the pain decreased
profoundly:from26to6outof45ontheSF-MPQ,andfrom
44 to 12 out of 100 on the NPSI. It must be stressed that his
quality of life increased profoundly (Table 1)wi t hn oa d v e r s e
eﬀects during the whole treatment period.
3. Discussion
This paper concerns the complexity of treating a patient suf-
fering from CRPS-1. Until now only a few controlled studies
on therapies of CRPS have been conducted [16]. Frequen-
tly, treatment regimes resulting from various studies of
neuropathic pain syndromes have been transferred to CRPS
patients [17]. Eﬃcacy of NSAIDs in CRPS patients has not
been systematically evaluated so far [4]. However, this class
ofdrugsisoftenusedastheprimarytherapy,priortoreferral
toaspecializedinstitution[16].Thereisinsuﬃcientevidence
that opioids and local anesthetics, such as lidocaine and botu
linum injections, are eﬀective in treating neuropathic pain
in CRPS [4]. On the other hand, there are indications that
ketamine, DMSO cream, antidepressants, and anticonvul-
sants are eﬀective in treating the neuropathic pain in CRPS
[4].
Before the patient of this case report was referred to our
clinic, several diﬀerent analgesics have been prescribed and
taken, however without success and with considerable
adverseeﬀects.Ourstrategywastoadministertopicalformu-
lations of evidence-based established analgesics for neuro-
pathicpainwithlocalizedactivity.Itwasalsoaimedatreduc-
ing the risk of peak-dose adverse eﬀects, usually seen after
taking oral medication [18, 19]. Probably both local and
systemic eﬀects resulted in pain reduction. On one hand, no
plasma levels of the active compounds were detected after
ketamine 10% [10]; on the other hand, adverse eﬀects wereCase Reports in Medicine 3
reported after amitriptyline 10%, possibly being a poor
metabolizer and therefore as a result an increased plasma
level [9]. Future research has to clarify this issue.
Topical strategy proved to be successful in our patient, as
no adverse eﬀects were reported.
The rationale of our multimodal stepped care approach
can be explained as follows. As the ﬁrst step of our treatment
schedule we selected topical amitriptyline 5%. It is well
known that oral amitriptyline is the ﬁrst choice in the
treatment of neuropathic pain, beause the numbers needed
totreatislow:2to3[20].Thismeansthat2or3patientshave
tobetreatedsothat1patienthasatleast50%painreduction.
It is also documented that the topical administration of
amitriptyline is eﬃcacious and safe in dosages of 2% to
4% in various neuropathic pain syndromes and is usually
combined with ketamine [21–23]. In previous history our
patient responded to some extent to oral amitriptyline; how-
ever, adverse eﬀects limited its use. Therefore, topical amitri-
ptyline was well justiﬁed.
In the second step we added topical ketamine. Several
small trials in CRPS patients supported the analgesic use of
ketamine [9, 11, 24–27], although most trials used other
forms, such as intravenous application. Ketamine acts on the
N-methyl-D-aspartic acid receptor (NMDAR), located on
nerve ﬁbers and in the central nervous system [28]. The
pain-reducing eﬀect of ketamine cream could be explained,
because increased inﬂammatory factors are present in CRPS,
and inﬂammation in the periphery increases the number of
NMDAR on peripheral nerve ﬁbers [29]. Our choice to use
topical ketamine 10% is based on a positive double-blind
cross-over trial [10].
In the third step we added DMSO 50% cream. The use of
DMSO as an analgesic in CRPS patients is well documented
[12–14].Furthermore,DMSOactsasapenetrationenhancer
for other topically administered drugs, in particular for ami-
triptyline and ketamine, which we used [15].
Medication as monotherapy is usually not suﬃcient to
treat eﬀectively neuropathic pain, such as in CRPS. Adverse
eﬀects can also be the cause of not reaching suﬃcient anal-
gesic doses. Multimodal therapy is well established in other
diseases such as hypertension, asthma and cancer [30–32].
Recent insights in treating neuropathic pain clearly indi-
cate the advantages of the multimodal approach targeting
diﬀerentlevelsofpainsignalingpathways[33,34].Therefore,
such a multimodal stepped care approach can be considered
inCRPSpatientswithsevereintractablepain,withthegoalof
achieving maximal analgesic eﬀects, minimal adverse eﬀects
and optimal compliance.
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